
Cellectar Biosciences announced on Monday that its therapy for Waldenstrom's macroglobulinemia (WM), a rare blood cancer, achieved its primary goal in a late-stage study. In the trial, 75.6% of WM patients experienced a reduction in cancer size or its disappearance with Cellectar's iopofosine. Additionally, 76% of those who completed the four-dose therapy remained progression-free for an average of eight months. The New Jersey-based company plans to seek accelerated FDA approval for iopofosine, aiming for a potential mid-2025 launch.
Like
Save
Share